DE69210286T2 - Behandlung von intraocularem Druck mit einer synergistischen Kombination - Google Patents

Behandlung von intraocularem Druck mit einer synergistischen Kombination

Info

Publication number
DE69210286T2
DE69210286T2 DE69210286T DE69210286T DE69210286T2 DE 69210286 T2 DE69210286 T2 DE 69210286T2 DE 69210286 T DE69210286 T DE 69210286T DE 69210286 T DE69210286 T DE 69210286T DE 69210286 T2 DE69210286 T2 DE 69210286T2
Authority
DE
Germany
Prior art keywords
pharmaceutically acceptable
keto
component
dihydro
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69210286T
Other languages
German (de)
English (en)
Other versions
DE69210286D1 (de
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK, R Tech Ueno Ltd filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Application granted granted Critical
Publication of DE69210286D1 publication Critical patent/DE69210286D1/de
Publication of DE69210286T2 publication Critical patent/DE69210286T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69210286T 1991-03-01 1992-02-20 Behandlung von intraocularem Druck mit einer synergistischen Kombination Expired - Lifetime DE69210286T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6132891 1991-03-01

Publications (2)

Publication Number Publication Date
DE69210286D1 DE69210286D1 (de) 1996-06-05
DE69210286T2 true DE69210286T2 (de) 1996-09-12

Family

ID=13167964

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69210286T Expired - Lifetime DE69210286T2 (de) 1991-03-01 1992-02-20 Behandlung von intraocularem Druck mit einer synergistischen Kombination

Country Status (11)

Country Link
US (1) US5547968A (esLanguage)
EP (1) EP0501678B1 (esLanguage)
JP (1) JP2511611B2 (esLanguage)
KR (1) KR100221369B1 (esLanguage)
AT (1) ATE137407T1 (esLanguage)
CA (1) CA2061907C (esLanguage)
DE (1) DE69210286T2 (esLanguage)
DK (1) DK0501678T3 (esLanguage)
ES (1) ES2089387T3 (esLanguage)
GR (1) GR3019820T3 (esLanguage)
TW (1) TW210287B (esLanguage)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270349A1 (en) * 1996-11-01 1998-05-14 Jesse A. May Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US7128903B2 (en) * 2001-10-03 2006-10-31 Innovative Pharmaceutical Concepts (Ipc) Inc. Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
TWI495471B (zh) * 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0242580B1 (en) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
EP0286903B2 (en) * 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
JPH0739343B2 (ja) * 1988-10-01 1995-05-01 株式会社アールテック・ウエノ 眼圧降下剤
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel

Also Published As

Publication number Publication date
JPH0565227A (ja) 1993-03-19
DK0501678T3 (da) 1996-05-28
ATE137407T1 (de) 1996-05-15
EP0501678A2 (en) 1992-09-02
JP2511611B2 (ja) 1996-07-03
KR920017654A (ko) 1992-10-21
CA2061907A1 (en) 1992-09-02
EP0501678A3 (en) 1992-12-16
KR100221369B1 (ko) 1999-09-15
EP0501678B1 (en) 1996-05-01
ES2089387T3 (es) 1996-10-01
TW210287B (esLanguage) 1993-08-01
CA2061907C (en) 2003-04-08
GR3019820T3 (en) 1996-08-31
US5547968A (en) 1996-08-20
DE69210286D1 (de) 1996-06-05

Similar Documents

Publication Publication Date Title
DE69232150T2 (de) Behandlung von Augenhochdruck mit Betablockern und Prostansäurederivaten
DE3850676T2 (de) Hypotensive okulare Mittel.
DE69129921T2 (de) Behandlung von Katarakt mit 15-keto-Prostaglandinderivaten
DE69511181T2 (de) Mittel für Behandlung der Leber-Gallenerkrankungen
DE68918391T2 (de) Okulare hypotensive Mittel.
DE69105349T2 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination zur ophthalmischen Verwendung.
DE69118978T2 (de) Behandlung von entzündlichen Erkrankungen mit 15-Ketoprostaglandinen
DE69106777T2 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
DE69116224T2 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
DE69024744T2 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
DE69210286T2 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination
DE69100171T2 (de) Synergistische Kombination zur ophthalmischen Verwendung.
DE69032000T2 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE69123892T2 (de) Behandlung von Katarakt mit prostacyclinverbindungen
US5175189A (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
DE69006964T2 (de) Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition